Royalty Report: Drugs, Cancer, Disease – Collection: 26159


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26159

License Grant
The Licensee, a specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of cancer and pain entered into a royalty Agreement with a doctor, the Licensor, under which the Licensee has an exclusive License to certain patents for Ceplene (histamine dihydrochloride or any other H2 receptor agonist) configured for the systemic treatment of cancer, infectious diseases, autoimmune diseases and other medical conditions.
License Property
Ceplene (histamine dihydrochloride) is the Licensee's lead oncology compound, administered in conjunction with low dose interleukin-2 (IL-2), for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML).
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 257597

License Grant
The Israeli Licensor, the technology transfer company of the University, granted Licensee an exclusive license, with a right to sub-license, to make commercial use of the licensed technology in order to develop, manufacture, market, distribute or sell products derived from the license.
License Property
The licensed technology includes patents, research results and know-how developed by Professor Simon Benita related to the NanomAbs technology.
Field of Use
The oncology portfolio includes Ceplene, which is approved in the European Union for the maintenance of remission in patients with Acute Myeloid Leukemia (“AML”) in combination with interleukin-2 (IL-2), a nanotechnology antibody platform, which we refer to as “NanomAbs,” and two vascular disrupting agents, Azixa and Crolibulin.

IPSCIO Record ID: 5229

License Grant
The Company grants a royalty-bearing, exclusive license under the Patent and under the Licensor's Information to make, have made, or use Licensed Product labeled for testing or trials, and upon proper regulatory approval, for use and sale to treat humans or animals in the United States.
License Property
Licensed Product means dose formulations or compositions containing any animal or human IFN-g designated, detailed or labeled for oral use including, but not limited to, administration for mucosal contact of the mouth and throat to treat or prevent the development of infections in humans or animals exposed to infectious agents, or suffering from autoimmune diseases, cancer, or connective tissue diseases.  United States Patent Application No. 60-156,480, dated September 28, 1999, relating to a method for using interferon-g('IFN-g') orally, and which, along with all modifications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.